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Abstract
BACKGROUND—The purpose of this study was to describe the development and early 
implementation of a national spina bifida (SB) patient registry, the goal of which is to monitor the 
health status, clinical care, and outcomes of people with SB by collecting and analyzing patient 
data from comprehensive SB clinics.
METHODS—Using a web-based, SB-specific electronic medical record, 10 SB clinics collected 
health-related information for patients diagnosed with myelomeningocele, lipomyelomeningocele, 
fatty filum, or meningocele. This information was compiled and de-identified for transmission to 
the Centers for Disease Control and Prevention (CDC) for quality control and analysis.
RESULTS—A total of 2070 patients were enrolled from 2009 through 2011: 84.9% were 
younger than 18 years of age; 1095 were women; 64.2% were non-Hispanic white; 6.5% were 
non-Hispanic black or African American; and 24.2% were Hispanic or Latino. Myelomeningocele 
was the most common diagnosis (81.5%).
CONCLUSIONS—The creation of a National Spina Bifida Patient Registry partnership between 
the CDC and SB clinics has been feasible. Through planned longitudinal data collection and the 
inclusion of additional clinics, the data generated by the registry will become more robust and 
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representative of the population of patients attending SB clinics in the United States and will allow 
for the investigation of patient outcomes.
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INTRODUCTION
Advances in medical care and technology have resulted in greater expected longevity for 
babies born with spina bifida (SB) (Bowman et al., 2001). As the life expectancy of 
individuals with SB increases, the number of adults in the United States living with SB is 
growing in spite of a diminishing incidence (Dillon, et al., 2000; Williams, et al., 2005). 
Meanwhile, knowledge regarding the health status and long-term health outcomes of people 
with SB is limited. This is significant because people with SB often experience preventable, 
condition-specific difficulties such as infections, pressure sores, and kidney stones, as well 
as secondary conditions such as renal failure, all of which detrimentally influence key 
aspects of their lives (Kinsman and Doehring, 1996). Prior attempts to collect SB-related 
patient information have used small convenience or clinic samples, which limit 
generalizability. To gain a better understanding of SB clinics in the United States, in 2005, 
the Spina Bifida Association (SBA) began a collaboration with the Agency for Healthcare 
Research and Quality, Centers for Disease Control and Prevention (CDC), Delmarva 
Foundation for Medical Care (Delmarva), and National Initiative for Children’s Healthcare 
Quality to survey these clinics. The goal of this effort was to obtain a clearer overall picture 
of patients attending SB clinics, gain an understanding of clinic operations and services, and 
elicit information related to care processes and outcomes with the goal of strengthening the 
quality of clinical care.
Based on this assessment and the experiences of other organizations (such as the Cystic 
Fibrosis Foundation [Goss et al., 2002]), the SBA Professional Advisory Council proposed 
the establishment of the National Spina Bifida Patient Registry (NSBPR). The goals of the 
proposed effort were to provide the infrastructure to support SB clinical research, to promote 
a systematic approach to describe the SB clinic population, and to document and improve 
the quality of SB clinical care by pooling data across multiple sites.
The primary focus of the NSBPR has been to describe the patient population attending SB 
clinics and to detect variations in processes of care that are associated with better health 
outcomes. This focus requires a clinic-based rather than a population-based SB patient 
registry (Gliklich and Dreyer, 2012). Although this approach excludes individuals who do 
not seek care from SB clinics, it provides a sample of patients who do attend these clinics 
for credible analyses of practices and outcomes. Further, care from an integrated, 
multidisciplinary, or interdisciplinary SB clinic is recommended best practice (Kaufman et 
al., 1994). The clinic-based approach is similar to that used by the Cystic Fibrosis 
Foundation Patient Registry, which has been successful in providing valid data for 
descriptive reports and hypotheses-driven analyses, and has served as a driver of quality 
improvement activities in the cystic fibrosis community (Schechter, 2008). The assumption 
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is that data provided from the clinics are reliable and by using the clinic as the unit of 
analysis, it is possible to obtain a more accurate report of the variety of treatments provided 
and a clearer picture of the relationship between these treatments and health outcomes. The 
purpose of this article is to describe the development, implementation, and early success at 
establishing the NSBPR. We aim to demonstrate the feasibility of launching and maintaining 
a patient data registry focused on SB clinics.
METHODS
Site and Patient Selection
In 2008, the CDC solicited applications from SB clinics to examine the feasibility of using a 
standardized tool to collect information on patients with SB. Clinics were eligible to apply if 
they had previously indicated interest in national SB efforts through participation in a 2005 
SBA survey, (which was described in the Introduction to this article), were 
multidisciplinary, and cared for a minimum of 250 patients with SB in the year before 
applying (to help ensure sufficient enrollment and clinic capacity during the piloting of the 
registry). Between September 2008 and August 2009, nine SB clinic sites (10 actual clinics; 
one site included two clinics) were funded to participate in the registry. Figure 1 also 
indicates newly funded clinics at which data collection had not begun at the time of 
manuscript development. After receiving institutional review board approval, clinics were 
expected to contribute longitudinal data on patients having one of four diagnoses, 
(myelomeningocele, meningocele, lipomyelomeningocele, or fatty filum), and consent and 
assent (based on youth’s age) to participate. Each enrolled patient would be followed 
longitudinally for the entire funded period. Clinics began enrollment in 2009 and, within 15 
months of the initial funding, all sites were collecting patient data. A descriptive summary of 
demographic data on those who did not participate is being collected at each site.
SB Registry Development
Selection of core registry variables—A group of SB health care professionals, parents 
and people affected by SB, and representatives of the SBA, CDC, Agency for Healthcare 
Research and Quality, and National Initiative for Children’s Healthcare Quality met in 
Washington, DC, to identify and discuss hundreds of variables considered to be critical to 
the care and lives of the population with SB. The list was reduced to 20 questions that were 
considered to be valid indicators of clinical status, feasible to collect, and definable in a 
uniform way (Schechter, 2008). These questions included basic demographic information; 
neurosurgery, orthopedic, and urologic procedures; growth measures; and outcomes such as 
mobility, continence, and pressure sores (See Supplemental Tables 1, 2, and 3, online only).
Data collection tool—Using the hemophilia treatment centers system as a model in 
which registry variables are embedded in an electronic medical record (EMR) (Versel, 
2010), a web-based Spina Bifida-Electronic Medical Record (SB-EMR) was developed to: 
(1) save time in record keeping and tracking, (2) enhance the quality and availability of data 
for clinical use and research, (3) facilitate data sharing for studies and collaborations, and (4) 
improve patient care through the proper comparison of care delivered and outcomes realized 
across clinical programs. The use of the SB-EMR to collect information from the 20 core 
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registry questions provides a reliable, standardized method for data collection and 
management for the clinics participating in the registry.
Data Entry and Data Quality Assurance
Both medical record abstraction and patient interview were the sources of patient data. Data 
were collected via standardized paper forms and entered into the SB-EMR, then reviewed 
for accuracy and completeness by clinic staff, after which the de-identified data were 
electronically transmitted to the CDC for further analysis.
To ensure the quality of registry data, systematic procedures were implemented at the SB 
clinic sites and at the CDC Data Management Center during the registry onset and 
implementation phase. For example, a ‘Report Functionality’ tool, a single page data 
summary screen, embedded into the EMR application as part of its build, prevents clinics 
from transmitting data to the CDC if data elements are missing. In addition to the Report 
Functionality tool, the compiled dataset goes through an automatic Quality Assurance/
Quality Control (QA/QC) system at the CDC. SAS software (version 9.3; SAS Institute Inc., 
Cary, NC) is used for data management and SAS macros were developed for data QA/QC to 
identify duplications, discrepancies, outliers, and data entry errors. The automatic system 
generates site-specific data quality reports that are sent to the corresponding clinics to check 
and correct the data as necessary. At each clinic site and at the initiation of data collection, 
confirmation of the information obtained from the medical record is performed for a 
minimum of 3 months. A minimum of 20% of the records submitted per month are 
randomly selected and all of the data elements are verified by someone other than the initial 
abstractor. (Table 1 has more detailed activities of the data quality assurance at clinic sites 
and the CDC.)
RESULTS
A total of 2070 patients were enrolled in the registry from 2009 to 2011. The patient 
enrollment ranged from 61 to 382 patients per clinic site with six sites each enrolling over 
200 patients. The rate of refusal per site ranged from none to 14.6% with an overall refusal 
rate of 6.5%.
Only a few of the participating clinics provide services to adults and thus the sample 
predominantly consisted of patients younger than 18 years. In addition, there were more 
women than men. Although primarily white, the ethnic diversity of the sample does reflect 
the underlying catchment area populations of the participating clinics. Individuals of 
Hispanic ethnicity have been reported to have a higher incidence of SB than black or 
African Americans and the sample reflects that pattern. Myelomeningocele was the 
predominant diagnosis and all levels of lesion are represented (Table 2).
There have been challenging issues in the interpretation of particular registry variables (i.e., 
urinary continence), which have been resolved through extensive discussion both on 
monthly coordinating committee conference calls and during annual coordinating committee 
meetings. The methods of collecting height and weight measurements are still under 
discussion, as variations in measurement practices have been detected across clinics.
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In an evaluation of data quality assurance procedures, quality of data transmitted before and 
after implementation of the Report Functionality tool in October 2010 was compared. 
Before the Report Functionality tool was available, missing values were as high as 15%. 
After the tool was activated in the EMR, missing values in core data elements (n = 1464 
patients) declined to <0.05% and data accuracy appeared to improve (Soe et al., 2011). In 
further efforts to improve data quality, the automatic QA/QC system was implemented in 
2011 followed by an evaluation of the procedures. In December 31, 2011, the CDC received 
cumulative data on 2070 registry participants from the original 10 sites. Data quality 
warnings were identified in two patients (0.10%) from demographics data and 35 patients 
(1.69%) from interventions and outcomes data (Liu et al., 2012).
DISCUSSION
The greatest challenges in researching a rare condition is the lack of information regarding 
the course of the disease and the effectiveness of treatments on a sufficient amount of 
individuals to allow for meaningful interpretations. The small numbers of patients and lack 
of patient diversity found in single clinics or in small groups of clinics can lead to bias in 
reporting the status of these conditions (Morgan et al., 1999). Thus, research relying on 
participant selection from single or small groups of clinics can be problematic. Based on the 
successful experiences of groups focusing on rare conditions such as cystic fibrosis (Morgan 
et al., 1999), Pompe disease (Byrne et al., 2011), and growth hormone deficiency (Pugeat, 
2004), the CDC in collaboration with the SBA has designed a registry to collect prospective 
and longitudinal information on patients from multiple SB clinics across the United States. 
In the first years of the registry, a process was developed to collect valid data, and, as of 
2011, 10 clinics have submitted data on more than 2000 patients. Condition-specific 
registries, such as this one, allow for observational studies that collect data to follow patterns 
in diagnoses, treatments, and outcomes over time in existing practice settings, affording the 
opportunity for robust analysis of pertinent issues (Gliklich and Dreyer, 2010).
Experience thus far has demonstrated that a network of SB clinics can be accessed to 
systematically document health care and health outcomes experiences. Building a 
partnership between the CDC and SB clinics in the United States will ensure that key 
stakeholders with an interest in optimal outcomes for individuals affected by SB have an 
influential voice in the pragmatic implementation of the registry. The clinics have worked 
together with the CDC to manage the operation of the registry, helping to guide analysis and 
interpretation of the data. Well-designed patient registries are powerful tools for 
understanding condition progression and management (Schechter, 2008). The goal of the 
NSBPR is to monitor systematically the course of SB, with the expectation that the 
variations in care and subsequent patient outcomes will suggest modifiable practices that are 
most successful.
Study Limitations and Future Direction
Transition from pediatric to adult care is an important issue to this and other populations 
with chronic complex conditions. Although not addressed in the early stages of the 
development and implementation of this registry, the NSBPR should heighten awareness of 
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the issue, as registry participants “age out” of their clinics and of the registry data collection 
system. Transition is a future interest of the registry and at least one site is piloting 
transition-specific items for future use in the registry.
Current practice of data abstraction and entry redundancy can also affect the long-term 
sustainability of the NSBPR. At this time, there is no automatic link between legacy medical 
record systems of participating SB clinics and the SB EMR software, which requires 
redundant entries of patient data into both the hospital medical record and the SB-EMR. 
Although in most cases it takes only a short time (3–5 minutes per patient) for a staff 
member to enter registry data annually, total resource use for this purpose is not clear. Use 
of the SB-EMR application can enhance care coordination and the maintenance of SB-
specific information to result in a more comprehensive and efficient approach to care 
provision and follow-up in the multidisciplinary SB clinic setting. Considering the data entry 
redundancy and its potential adverse impact on the sustainability of the NSBPR, as well as 
the value of the SB-EMR, to clinic functions and care coordination, the SBA is funding a 
study at three clinics participating in the registry to explore the feasibility of automatically 
transferring data from a legacy EMR into the SB-EMR and to demonstrate the utility of the 
SBEMR application to facilitate and improve the logistics of managing SB clinic functions. 
Results from this study are anticipated in late 2012.
A registry that focuses on patients of SB clinics might not be representative of the entire SB 
population, because the percentage of the SB population that attends SB clinics is not 
known. There are a variety of reasons for people with SB to not attend a clinic, including the 
unavailability of age-appropriate services for adults, a lack of funding for travel and time 
away from work, geographic remoteness, and a family’s wish to use specialists of their own 
choosing and scheduling. Patients in good health might place a lower priority on attending 
an SB clinic for these or other reasons. Because the health status of those not attending SB 
clinics is an area of importance, efforts to identify and collect data on patients not attending 
SB clinics will be included in future research.
CONCLUSION
The NSBPR was designed and created through a partnership between the CDC and the SBA 
along with a core group of 10 SB clinics to monitor clinical care and the health status of 
patients attending comprehensive SB clinics. The goals of the registry are to describe the 
demographic and condition-relevant characteristics of the SB population, provide a platform 
for clinical and epidemiologic research, and to allow comparisons of clinical care and 
outcomes among clinics for benchmarking purposes and quality improvement. Having 
demonstrated the feasibility of the effort through successful recruitment and data collection, 
the current plan is to expand the registry into additional clinics and enroll more patients into 
the longitudinal database. Further, interested researchers and clinicians will be recruited to 
participate and use the data for analyses and initiatives that will allow the realization of our 
goals.
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Geographic distribution of multidisciplinary clinics in the National Spina Bifida Registry 
project, 2011.
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Table 1
Procedures at the CDC Data Management Center and local sites during different stages of registry 
development and implementation for the assurance of data quality (modified from Arts et al., 2002)
CDC Data Management Center Local clinic sites
Registry onset
• SB Registry elements finalized and data collection forms 
developed by participating clinicians and CDC SB team 
staff.
• Data and data characteristics defined.
• Data collection and data audit protocols developed.
Registry onset
• Clinic site staff member designated by Principal 
Investigator to manage data quality assurance.
• Site staff reviewed overview of study, abstraction 
procedures, data collection procedure, and progress 
reports.
• Clinic site study staff participated in training for data entry 
and edit using the SB-EMR.
Implementation
• Edit checks embedded in SB-EMR.
• Report functionality embedded in SB-EMR to prevent 
transmission of reports with missing data.
• User friendly data abstraction forms developed.
• Data quality assurance plan developed.
Implementation
• System to monitor reliability and completeness of data 
designed and implemented.
• Clinic staff determined the validity and completeness of 
data from data extraction sources such as medical records.
Ongoing
• Continuous communication/encouragement conducted 
with sites.
• Forms, software, data dictionary, protocol, training 
material, etc., amended when indicated.
• Data transmitted via the secure data transmission network 
logged and tracked for transmission errors.
• Regular conference calls convened with SB registry data 
committee.
• During site visits: data quality audit conducted comparing 
central registry data with source data, causes of 
discrepancies discussed, local data collection and entry 
procedures observed.
• Automatic data checks performed and site-specific data 
quality reports generated.
• Data quality reports provided to sites.
• Causes of data errors resolved and local correction of data 
errors facilitated.
Ongoing
• New clinic staff/chart abstractors trained.
• Data collection/entry staff and PIs communicated 
frequently.
• Data definitions reviewed with all staff as indicated.
• Functionality of updated software application evaluated 
and issues reported.
• CDC informed regarding any issue/concern regarding the 
data.
• SB EMR application report screens analyzed for missing 
and inaccurate data.
• Case counts reviewed by using the application’s analytic 
function, eWebReports ‘Exago, Inc., Shelton, CT’.
• Accuracy and completeness of data validated via a 
bimonthly review by another person (20% records) for 3 
months when data-entry staff persons join the project.
• Investigated errors detected at local sites and in quality 
reports from the Data Management Center.
Future
• A large scale reliability study in all sites will be 
conducted in 2013.
Future
Participate in reliability study.
CDC, Centers for Disease Control and Prevention; SB, spina bifida; PI, XXX; SB-EMR, Spina Bifida-Electronic Medical Record.
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Table 2
Patient Demographics
Variable No. of patients (%)
Age at enrollment (yrs)
Younger than 2 349 (16.9)
2 to <5 330 (15.9)
5 to <10 431 (20.8)
10 to <13 245 (11.8)
13 to <18 403 (19.5)
18 to <22 200 (9.7)





Non-Hispanic white 1309 (64.2)
Non-Hispanic black 132 (6.5)






Fatty Filum 49 (2.4)
Level of lesion
Thoracic (flaccid lower extremities) 295 (14.3)
High-lumbar (hip flexion present) 197 (9.5)
Mid-lumbar (knee extension present) 530 (25.6)
Low-lumbar (foot dorsiflexion present) 370 (17.9)
Sacral (foot plantar flexion present) 678 (32.8)
Note: Site distribution ranged from 61 (2.9%) to 382 (18.5%).
SB, spina bifida.
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